FDA Class II Recall: Wizcure Pharmaa's BioGlo Fluorescein Sodium Ophthalmic Strips Face Sterility Assurance Deficiencies
Wizcure Pharmaa Private Limited has initiated a Class II nationwide recall of 184,320 containers of BioGlo Fluorescein Sodium Ophthalmic Strips USP due to a lack of sterility assurance stemming from cGMP non-conformance at manufacturer Omni Lens PVT. Ltd. This event underscores critical supply chain vulnerabilities for sterile ophthalmic products and demands immediate action from procurement and regulatory teams.
FDA Class II Recall: BioGlo Ophthalmic Strips Face Sterility Assurance Deficiencies
Wizcure Pharmaa Private Limited has initiated a Class II recall (D-0352-2026) for all lots of its BioGlo Fluorescein Sodium Ophthalmic Strips USP, impacting 184,320 containers distributed nationwide across the USA. The critical reason cited for this voluntary, firm-initiated recall is a 'Lack of Assurance of Sterility,' directly attributed to the products not being manufactured in conformance with current Good Manufacturing Practices (cGMP). This event, initiated on December 31, 2025, and classified by the FDA on February 25, 2026, signals a significant quality control failure at the manufacturing level. For procurement directors, this means an immediate need to identify and quarantine all affected stock of NDC 17238-900-11 within your supply chain, preventing further distribution or use. Regulatory affairs heads must understand that cGMP non-conformance, particularly concerning sterility, is a high-priority issue for the FDA, indicating fundamental systemic failures in quality management. This recall, originating from a facility in India, highlights the persistent challenges in maintaining consistent quality standards across global pharmaceutical supply chains, posing direct risks to patient safety and operational continuity for healthcare providers relying on these diagnostic tools.
Manufacturing Origin and Critical Product Impact: Omni Lens PVT. Ltd.'s Role
The recalled BioGlo Fluorescein Sodium Ophthalmic Strips USP are manufactured by Omni Lens PVT. Ltd., located in Ahmedabad, Gujarat, India. These diagnostic strips are essential for ophthalmic examinations, where maintaining absolute sterility is paramount to prevent ocular infections and ensure patient safety. The identified cGMP non-conformance directly undermines the sterility assurance for a product used in a highly sensitive area of the human body. For quality assurance and regulatory teams, this incident necessitates a rigorous review of all suppliers, especially those manufacturing sterile products in regions with known regulatory oversight challenges. The involvement of Omni Lens PVT. Ltd. as the manufacturer, with HUB Pharmaceuticals, LLC in Scottsdale, AZ, serving as the US distributor, illustrates a complex global supply chain where manufacturing quality in one region directly impacts market access and patient safety in another. Business development executives should assess the competitive landscape for ophthalmic diagnostics, as this recall creates a potential void for alternative, reliably sterile products. This event underscores that even seemingly low-cost diagnostic consumables require the highest level of manufacturing integrity to avoid significant market disruption and reputational damage.
Supply Chain Exposure and Market Disruption for Ophthalmic Diagnostics
The nationwide distribution of BioGlo Fluorescein Sodium Ophthalmic Strips USP in the USA means that healthcare providers, pharmacies, and distributors across the country are directly exposed to this recall. With 184,320 containers affected, the immediate impact is a significant disruption in the availability of a standard ophthalmic diagnostic tool, NDC 17238-900-11. HUB Pharmaceuticals, LLC, as the listed distributor, faces the immediate challenge of managing the recall logistics and addressing customer concerns. Procurement directors must act swiftly to identify alternative sources for fluorescein sodium ophthalmic strips to maintain continuity of care in clinics and hospitals. This incident highlights the inherent risks of relying on a single supplier or a concentrated supply base for critical medical consumables. Supply chain VPs should leverage this event to stress-test their contingency plans for product shortages and quality-related recalls, particularly for sterile products. The financial implications extend beyond the cost of returned goods, encompassing potential patient adverse events, reputational damage, and the significant operational burden of managing a widespread recall. Robust supplier diversification and continuous monitoring of manufacturer compliance are non-negotiable strategies to mitigate such market disruptions.
Navigating Sterility Risks: Broader Industry Context and Sourcing Strategy
The recall of BioGlo Fluorescein Sodium Ophthalmic Strips due to sterility assurance issues is not an isolated incident but reflects a broader, persistent challenge within the global pharmaceutical and life sciences industry. Recent parallel events underscore this trend: Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility failures in June 2026, and Spectra Medical Devices encountered similar deficiencies with its Lidocaine HCl Injection. Sun Pharmaceutical's Fluocinonide recall in April 2026 also signaled persistent quality control challenges. For supply chain VPs and procurement directors, these recurring events emphasize the critical need for a proactive and diversified sourcing strategy for all sterile products. Relying solely on cost-efficiency without rigorous quality oversight is an unsustainable model. Companies must invest in enhanced supplier qualification programs, including unannounced audits and comprehensive cGMP assessments, particularly for facilities in emerging markets. This strategic shift protects against not only immediate supply disruptions but also the long-term erosion of trust and market share. Business development executives should identify and cultivate relationships with manufacturers demonstrating a consistent track record of cGMP compliance and robust quality systems to secure resilient supply lines.
Regulatory Implications and Future Compliance Outlook for Omni Lens and Wizcure
A Class II recall stemming from cGMP non-conformance, especially concerning sterility, places Omni Lens PVT. Ltd. and its partners, including Wizcure Pharmaa Private Limited, under significant FDA scrutiny. While the source text details a firm-initiated recall, such events often precede or accompany more formal regulatory actions. The FDA's focus will be on the adequacy of corrective and preventive actions (CAPA) implemented by Omni Lens to address the root causes of the sterility assurance failures. Regulatory affairs heads must anticipate potential FDA inspections of the Omni Lens facility in Ahmedabad. Failure to demonstrate comprehensive and effective remediation could escalate to a formal FDA Warning Letter, detailing specific cGMP violations, and potentially lead to an Import Alert, effectively banning products from that facility from entering the U.S. market. For companies sourcing any products from Omni Lens, this signals an urgent need to conduct their own due diligence and prepare for potential supply chain interruptions. Proactive engagement with contract manufacturers to ensure robust quality systems and transparent communication with regulatory bodies are critical to mitigating future compliance risks and safeguarding market access.